The Department of Veterans Affairs Veterans Health Administration awarded a $12,725 delivery order to Incyte Corporation under GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB) to provide PEMIGAINIB. The contract has a period of performance from December 12, 2023 through February 12, 2024 for delivery to a VA medical facility located in Talleyville, Delaware. GSA Schedule FSS-61-IB facilitates acquisition of pharmaceuticals and drugs by federal agencies to support patient care programs. This delivery order indicates the VA facility will receive PEMIGAINIB, a drug developed by Incyte Corporation, to address needs within the Veterans Health Administration network in the mid-Atlantic region during the specified two-month timeframe.
Generated 12/20/23, 2:28 PM